LAUSR

Abstract Background and Aims Preliminary reports indicate that AKI (acute kidney injury) seem to be associated with coronavirus disease 2019 (COVID-19) severity and outcomes. Although the reported incidence of AKI among hospitalized patients with COVID-19 varies widely, AKI among hospitalized patients is associated with poor prognosis. The aim of this study was to evaluate the clinical characteristics and outcomes in our COVID-19 patients who developed AKI during intensive care unit hospitalization. Method In our retrospective, observational study COVID-19 PCR positive 49 patients who were hospitalized with COVID-19 pnumoniae in intensive care unit and developed AKI were evaluated with demographics, laboratory data, treatment and outcome. The prognostic nutritional index (PNI), which is calculated using the serum albumin concentration and total lymphocytic count were also evaluated. All patients were treated with favipiravir+low molecular weight heparin; laboratory tests were recorded before and after favipiravir treatment. Results Of 49 patients; 28 were male. A total of 9/49 (18.4%) patients survived. All patients were treated with favipiravir; laboratory tests were recorded before and after favipiravir treatment. The clinical parameters of patients are shown in Table-1 and Table-2. Mean PNI of the patients who survived was higher than patients who were exitus. Conclusion AKI in hospitalized patients with COVID-19 was associated with high mortality. Of all patients with AKI, only 18.4% survived. Discharged n= 9 Dead n=40 p Age 78.3±6.6 74.8±13.4 0.451 Gender (male/female) 5/4 23/17 1.000 PNI 32.4±7.2 25.2±6.3 0.049 WBC 10.4±5.6 16.8±10.4 0.017 Neutrophil 8.3±5.8 14.3±9.2 0.011 Lymphocyte 1.26 (0.55-1.80) 0.64 (0.40-1.33) 0.159 NLR (Neutrophil/ Lymphocyte Ratio) 5.59 (3.48-10.47) 19.7 (10.5-28) 0.025 Hemoglobin (g/dL) 10.6±1.8 10.8±2.3 0.877 Creatinine 2.15±0.96 2.19±1.53 0.597 LDH 213 (164-312) 683 (293-1379) <0,001 AST 16 (12-34) 43 (26-87) 0.012 Troponin T 0.042 (0.024-0.078) 0.109 (0.056-0.0583 0.050 Procalcytonin 0.195 (0.145-0.253) 0.945 (0.310-2.448) 0.070 Ferritin 240 (99-872) 690 (456-1238) 0.048 D-dimer 604 (425-1895) 4083 (1898-6376) 0.003 CRP 19.3 (14.2-35.7) 142.0 (85.6-259.3) <0.001 Before treatment After treatment p PNI 32.1±7.2 25.2±6.3 <0.0001 WBC 12.3±8.5 16.8±10.4 0.011 Neutrophil 10.1±7.7 14.3±9.2 0.012 Lymphocyte 0.80(0.51-1.41) 0.64(0.40-1.33) 0.973 Hemoglobin (g/dL) 11.4±2.47 10.8±2.3 0.008 NLR 11.2(4.3-19.2) 19.7 (10.5-28) 0.013 CRP (mg/dL) 110.5 (35.8-147.9) 142(85.6-259.3) 0.009 Creatinin (mg/dL) 1.49±1.21 2.19±1.53 0.033 LDH 398 (282-592) 683 (293-1379) 0.011 Troponin T 0.057(0.021-0.234) 0.109 (0.056-0.583) 0.004 Procalcitonin 0.275 (0.140-2.220) 0.945 (0.310-2.448) 0.327 Ferritin 514 (239-1210) 690 (456-1238) 0.026 D-dimer 2451 (997-4955) 4083 (1898-6376) 0.045 MO392   Figure 1: Clinical and laboratory findings of patients after favipiravir treatment.MO392   Figure 2: Laboratory findings of the non-survived patients before and after favipiravir treatment (n=40).